Alzheimer disease (AD) is associated with the accumulation in the brain of extracellular neuritic plaques composed mainly of β-amyloid (Aβ) and of intracellular neurofibrillary tangles composed of hyperphosphorylated forms of the microtubule-associated protein tau. It is also associated with other features that have received less attention, including aberrant phospholipid, cholesterol, and calcium metabolism, and altered mitochondrial function and dynamics. The underlying mechanism(s) that might explain these observations are currently unknown. We recently showed that presenilin-1 (PS1), presenilin-2 (PS2), and γ-secretase activity, which processes the amyloid precursor protein (APP) to generate Aβ, are located predominantly in a specialized subcompartment of the endoplasmic reticulum (ER) that is physically and biochemically connected to mitochondria, called mitochondria-associated ER membranes (MAM). MAM is an intracellular lipid raft-like structure intimately involved in cholesterol and phospholipid lipid metabolism, in calcium homeostasis, and in mitochondrial function and dynamics. The coincidence of the functions associated with MAM with the symptomatology of AD led us to speculate that presenilins play a role in maintaining MAM function. We found that, consistent with this supposition, both MAM function and ER-mitochondrial connectivity are increased significantly in AD, which may help explain many of the biochemical and morphological features of the disease. Based on these findings, we propose that AD is fundamentally a disorder of ER-mitochondrial communication (the "MAM hypothesis"). This article is part of a Special Issue entitled 'Mitochondrial function and dysfunction in neurodegeneration'.
Introduction
Alzheimer disease (AD), the most common late-onset neurodegenerative dementing disorder, is characterized by progressive neuronal loss, especially in the cortex and hippocampus (Goedert and Spillantini, 2006) . The two main neuropathological hallmarks currently used to diagnose AD are the accumulation of intracellular neurofibrillary tangles, consisting mainly of hyperphosphorylated forms of the microtubule-associated protein tau within paired helical filaments, and the deposition of extracellular neuritic plaques containing numerous components, most prominent among them β-amyloid (Aβ), a small peptide derived from processing of the amyloid-β precursor protein (APP; gene APP) (Goedert and Spillantini, 2006) . As in other neurodenegenerative disorders, such as Parkinson disease and amyotrophic lateral sclerosis, the vast majority of cases of AD are Molecular and Cellular Neuroscience 55 (2013) [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] sporadic. However, in about 1% of patients the disease is inherited (usually in an autosomal-dominant manner) as a result of mutations in one of three genes: APP, PSEN1 (presenilin-1; PS1), and PSEN2 (presenilin-2; PS2). Notably, these three genes are related functionally, as presenilins are components of the γ-secretase complex that, after cleavage of APP by β-secretase (BACE1), cuts the C-terminal transmembrane domain of APP to produce Aβ (Fig. 1) . The Aβ fragments are of varying lengths, most commonly 40 and 42 aa, with the ratio of Aβ 42 :Aβ 40 increased in AD. Clinically, familial AD (FAD) is similar to the sporadic form (SAD), but has an earlier age of onset and is more aggressive (Jayadev et al., 2010) .
The most widely-accepted model of AD pathogenesis is called the "amyloid cascade" hypothesis (Hardy and Higgins, 1992) . It states that the disease arises when APP is processed to Aβ, which accumulates in the plaques; the Aβ -and in particular A β42 -is toxic to cells (in distinction to the "less toxic" Aβ 40 species); the resulting stress promotes tau hyperphosphorylation via upregulated calciumsensitive kinases, leading to the tangles (Hardy and Selkoe, 2002) . In many ways, the hypothesis has been highly successful, in that it unites findings from many different approaches to the disease and, most compellingly, helps explain how mutations in both the key enzymatic component of the γ-secretase complex (i.e. presenilin) and its substrate (i.e. APP) can cause the familial form of the disease. This, in turn, has driven thinking in the field to focus almost exclusively on plaques and on Aβ deposition as the key precipitating events in pathogenesis, leading to therapeutic strategies devoted to eliminating Aβ production. The failure of all therapeutic trials based on this premise (Marchesi, 2012 ) is a challenge to the hypothesis (Pimplikar, 2009) , and could be telling us that interdicting APP processing, which after all, is a normal cellular function, is counterproductive.
In addition, the amyloid hypothesis does not address other questions central to understanding pathogenesis (Castellani et al., 2002; Korczyn, 2008; Pimplikar, 2009; Reitz, 2012) . Notably, the accumulation of plaques and tangles occurs after the appearance of other symptoms, such as mitochondrial dysfunction (Gillardon et al., 2007; Wang et al., 2009) , elevated levels of circulating cholesterol (Stefani and Liguri, 2009) , altered metabolism of fatty acids and phospholipids (Fraser et al., 2010; Pettegrew et al., 2001) , and aberrant calcium homeostasis (Bezprozvanny and Mattson, 2008) . These features have received less attention, mainly because there is no unifying conceptual framework within the amyloid cascade hypothesis that would explain their occurrence (Schon and Area-Gomez, 2010) .
Because these issues pose a challenge to the amyloid cascade hypothesis, various alternative hypotheses have been put forward to explain not only these aspects of AD symptomatology (Puglielli et al., 2003; Smith et al., 2005) , but also inflammation (Ringheim and Szczepanik, 2006; Salminen et al., 2009) , endoplasmic reticulum (ER) stress (Costa et al., 2010; Hoozemans et al., 2005; Salminen et al., 2009; Unterberger et al., 2006) , hypoxic stress (Sun et al., 2006; Zhang and Le, 2010) , and mitochondrial dysfunction and oxidative stress (Castellani et al., 2002; Wang et al., 2009) . It is unclear whether these phenomena are causally linked, and it is a major challenge to try to subsume all of these features, as well as the plaques and tangles, under a single hypothesis of pathogenesis, if indeed such a unitary hypothesis exists.
A different way of thinking about AD pathogenesis
Part of the challenge in explaining pathogenesis has been the difficulty in determining where some of the key biochemical players reside within the cell, and the fact that spatial and temporal modifications to relevant protein and lipid constituents can alter their trafficking and subcellular localizations. This problem has been particularly contentious in the case of the presenilins, which are highly hydrophobic multi-pass transmembrane proteins that have been reported to be localized in virtually every membranous compartment of the cell, including the ER (De Strooper et al., 1997) , Golgi (De Strooper et al., 1997) , endosomes/lysosomes (Vetrivel et al., 2004) , the nuclear envelope (Kimura et al., 2001) , the plasma membrane (Marambaud et al., 2002) , and mitochondria (Hansson et al., 2004) . We believe that our understanding of the pathogenesis of AD is highly dependent on a precise understanding of the subcellular localization of this key proteolytic event.
Another confounding issue has been the finding that APP, presenilins, Aβ, and γ-secretase activity are enriched in lipid rafts (Kosicek et al., 2010; Urano et al., 2005; Vetrivel et al., 2005) . Lipid rafts are specialized domains rich in cholesterol and sphingolipids that have a liquid-ordered structure with unique biophysical characteristics that differ from the rest of the cell's liquid-disordered membranes, and that form so-called detergent-resistant membranes, or DRM's (Simons and Vaz, 2004) . Traditionally, lipid rafts have been considered to be present only in the plasma membrane (PM) (Simons and Vaz, 2004) , but this raises a conceptual problem -called "the spatial paradox" -because γ-secretase activity is negligible in the PM (Cupers et al., 2001) .
We recently discovered that the presenilins are indeed located predominantly in the ER (Area-Gomez et al., 2009) , confirming what has been found by others (De Strooper et al., 1997; Georgakopoulos et al., 1999). However, within the ER the presenilins are not distributed homogeneously. Rather, they are highly enriched in a subcompartment of the ER called mitochondria-associated ER membranes (ER-MAM, or MAM) (Area-Gomez et al., 2009) . Equally remarkable, we also found that not only PS1 and PS2, but also the majority of the γ-secretase activity present in mouse brain was highly concentrated in the MAM (Area-Gomez et al., 2009) . Thus, both the APP-cleaving enzyme (γ-secretase) and its substrate (APP) are present predominantly in this ER subcompartment.
MAM is a dynamic and highly specialized subdomain of the ER that is connected physically and biochemically to mitochondria (Csordas et al., 2006; Hayashi et al., 2009; Rusinol et al., 1994) (Fig. 2) . It is formed as a direct result of the apposition (on the order of nanometers) of bulk ER with mitochondria (de Brito and Scorrano, 2008; Fujimoto et al., 2012) , triggering specialized functions involving both organelles (Hayashi et al., 2009; Vance, 1990) . As opposed to other subcellular organelles, MAM is a dynamic subcompartment of the cell, with its composition varying in "real time," depending on circumstance. For example, cellular redox state and protein palmitoylation are at least two determinants of whether a protein does, or does not, partition to the MAM Lynes and Simmen, 2011; Lynes et al., 2012) . Approximately 75 proteins have been reported to be associated with MAM (Table 1) , including those involved in calcium homeostasis (e.g. IP3 receptors (Csordas et al., 2010; Mendes et al., 2005; Szabadkai et al., 2006) ), cholesterol metabolism (e.g. acyl-CoA:cholesterol acyltransferase [ACAT1; gene SOAT1] (Rusinol et al., 1994) ), and phospholipid metabolism (e.g. phosphatidylserine synthase 2 [PTDSS2] (Stone and Vance, 2000) ). Contacts between the two organelles are maintained by proteins such as phosphofurin acidic cluster sorting protein 2 (PACS2), which stabilizes and regulates the interaction of ER and mitochondria (Simmen et al., 2005) , and mitofusin-2 (MFN2), which is also required for mitochondrial fusion (de Brito and Scorrano, 2008) .
Importantly, MAM has now been shown to be a detergent-resistant membrane domain of the ER (Area-Gomez et al., 2012; Fujimoto et al., 2012; Hayashi and Fujimoto, 2010; Williamson et al., 2011) . In other words, it appears to be an intracellular lipid raft, which is not surprising, given the need for a higher structural order in this domain to regulate the synapsis between ER and mitochondria. If so, the localization of presenilins and γ-secretase activity in MAM may help resolve the unexplained finding that PS1 and γ-secretase activity are enriched in cholesterol-rich membrane microdomains (i.e. lipid rafts) (Vetrivel et al., 2004) , as well as help resolve the "spatial paradox" (Cupers et al., 2001 ). It could also account for the reported localizations of PS1 (Hansson et al., 2004) , APP (Anandatheerthavarada and Devi, 2007) ; Aβ (Du et al., 2008) , and tau (Perreault et al., 2009 ) at or in mitochondria (Schon and Area-Gomez, 2010) .
Could AD be a consequence of MAM dysfunction and altered ER-mitochondrial communication?
Since presenilins and γ-secretase activity are concentrated in the MAM, we hypothesized that genetic or biochemical alterations in these factors might affect some aspect or aspects of MAM function that would be relevant to the pathogenesis of AD. In agreement with this prediction, we have found that, as described below, MAM function and ER-mitochondrial communication are increased significantly in PS-knockout cells, in PS-knockdown cells, and in fibroblasts from both FAD and SAD patients (Area-Gomez et al., 2012); notably, this increased MAM function correlated with a significantly increased area of apposition between ER and mitochondria (see examples in Fig. 3 ). While the results in cells from FAD patients with mutations in PS1 and PS2 are consistent with our hypothesis, we were surprised to find that the same altered MAM phenotypes were present in cells from SAD patients, in which the presenilin genes are structurally normal (Area-Gomez et al., 2012) . This striking result prompted us to consider that MAM dysfunction and upregulated ER-mitochondrial communication, rather than altered γ-secretase behavior per se, is the common denominator underlying the pathogenesis of all forms of AD. 
MAM and cholesterol metabolism in AD
Patients with AD have elevated circulating total cholesterol (Martins et al., 2009; Stefani and Liguri, 2009 ), elevated cholesteryl esters (CE) in fibroblasts (Pani et al., 2009a (Pani et al., , 2009b ) and brain (Chan et al., 2012) , and an accumulation of neutral lipids (including CE) in lipid droplets in fibroblasts (Pani et al., 2009a (Pani et al., , 2009b and neurons (Gómez-Ramos and Asunción Morán, 2007), but the reason for these features are unknown. The intracellular conversion of free cholesterol to cholesteryl esters is catalyzed principally by acyl-CoA: cholesterol acyltransferase 1 (ACAT1) , thereby controlling the dynamic equilibrium between membrane-bound free cholesterol and cholesteryl esters stored in cytoplasmic lipid droplets (Puglielli et al., 2003) . Relevant to the MAM hypothesis, we (Area-Gomez et al., 2012) and others (Rusinol et al., 1994) have found that ACAT1 is highly enriched in the MAM (Fig. 2) . Moreover, we have found that in cells containing mutations in presenilins, and in FAD and SAD fibroblasts, ACAT1 activity is significantly increased, as is the formation of lipid droplets (Area-Gomez et al., 2012), similar to the findings of others described above.
This upregulation of MAM-localized ACAT1 in AD is intriguing because ACAT1 is absolutely required for both APP processing Huttunen et al., 2009a Huttunen et al., , 2009b and for the generation of Aβ (Puglielli et al., 2001) , by an unknown mechanism. Given that the activities of both ACAT1 and γ-secretase are located in the same compartment (i.e. MAM), perhaps one may affect the other as part of the cell's efforts to maintain tight cholesterol homeostasis. Cholesterol esterification by ACAT is not only a way for the cell to transport cholesterol among membranes, but is also a way to eliminate excess free cholesterol that would otherwise be toxic (Tabas, 2002; Warner et al., 1995) . Another way to reduce the concentration of free cholesterol is by cholesterol oxidation that results in a concomitant increase in cellular oxysterols via, for example, the conversion of cholesterol to 24(S)hydroxycholesterol (24SOH) (by cholesterol-24 hydroxylase [CYP46A1], a brain-specific enzyme) ; 24SOH, in turn, induces a further decrease in cholesterol synthesis via inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase Chang et al., 2010; Tabas et al., 1986; Wang et al., 2008) . Notably, 24SOH also reduces the cellular content of APP , by an unknown mechanism, although one possibility is that APP, which binds cholesterol (Barrett et al., 2012; Beel et al., 2008) , may act as a cholesterol sensor (Beel et al., 2008; Bryleva et al., 2010) . Furthermore, depletion of cholesterol causes a reduction in the interaction between PS1 and APP and the cleavage of the latter by γ-secretase (Guardia-Laguarta et al., 2009). Thus, it is plausible that the reduction in APP cleavage in ACAT1-KO Fig. 3 . Representative electron micrographs of mitochondria (M) apposed to ER (i.e. at MAM; arrowheads) in fibroblasts from a control subject, an SAD patient, and two FAD patients. Note the unusually large area of apposition in the AD patients. Size bars, 100 nm. Membrane GPI-anchored glycoprotein PRNP (Mattei et al., 2011) mice ) is a consequence of the altered cholesterol concentration in membranes due to inhibition of HMG-CoA reductase. In sum, while yet-unknown direct interactions among APP, ACAT1 and PS's may exist, these published data point towards cholesterol concentration in membranes, and more specifically in the MAM, as a regulator of the activity of these proteins. However, there is no persuasive evidence that mutations in ACAT1 cause AD (Lamsa et al., 2007; Papassotiropoulos et al., 2005; Wollmer et al., 2003; Zhao et al., 2005) , implying that altered ACAT levels are probably a result, not a cause, of AD.
MAM and phospholipid metabolism in AD
MAM and its communication with mitochondria are intimately involved in phospholipid metabolism and transport (Hayashi et al., 2009) . This is illustrated very nicely by the pathway for the synthesis of three of the cell's main phospholipids, phosphatidylserine (PtdSer), phosphatidylethanolamine (PtdEtn), and phosphatidylcholine (PtdCho): PtdSer is synthesized in the MAM via phosphatidylserine synthase 2 (PTDSS2); it then translocates to mitochondria (Voelker, 1989) , where it is converted to PtdEtn by phosphatidylserine decarboxylase (PISD); PtdEtn then translocates back to the MAM, where it is converted to PtdCho by phosphatidylethanolamine methyltransferase (PEMT) (Vance, 2003) (Fig. 2) . Because both ER and mitochondria are required in this pathway, the kinetics of phospholipid synthesis can be used as a measure of MAM function and ER-mitochondrial connectivity (Schumacher et al., 2002) . Using such an approach, we have found significantly upregulated ERmitochondrial phospholipid transport in presenilin-mutant and AD patient cells (Area-Gomez et al., 2012) . Notably, significant changes in the levels of these phospholipids have been found in AD patients (Nitsch et al., 1992; Pettegrew et al., 2001; Zhou et al., 2007) , buttressing our view that MAM plays an important role in the pathogenesis of AD (Schon and Area-Gomez, 2010) .
Deranged lipid metabolism might play a role in tau hyperphosphorylation. It has been shown that lipids, including cholesterol and sphingomyelin, interact with AD-associated paired helical filaments (Gellermann et al., 2006) , and that tau phosphorylation was stimulated in vitro by upregulation of calcium-activated kinases mediated by phospholipids (particularly PtdEtn) (Baudier and Cole, 1987) . The implication of these observations is that tau phosphorylation can be modulated by the phospholipid composition of the membranes with which it interacts.
MAM and calcium signaling in AD
Given that the two main subcellular organelles responsible for maintaining calcium homeostasis are the ER and the mitochondria (Berridge, 2002; Mironov and Symonchuk, 2006) , it is not surprising that MAM plays a key role in calcium trafficking (Hayashi et al., 2009) . As shown in Table 1 , there are at least 11 calcium-related proteins enriched in MAM, including ryanodine receptors (García-Pérez et al., 2008; Kopach et al., 2008) , inositol-1,4,5-trisphosphate (IP3) receptors (Mendes et al., 2005; Szabadkai et al., 2006) , and the sigma-1 receptor (Hayashi and Su, 2007) (Fig. 2) . We note that both wild-type PS1 and PS2 interact directly with IP3 receptors to regulate calcium gating between ER and mitochondria (Cheung et al., 2008) , and that FADlinked mutations in both proteins enhance this effect (Cheung et al., 2008 (Cheung et al., , 2010 , likely explaining the observed overload in intracellular Ca 2+ stores in AD (Supnet and Bezprozvanny, 2010) . As a result, when Ca 2+ is released from these intracellular stores, cytoslic Ca increased ER-mitochondrial communication in AD would almost certainly perturb such signaling, thereby explaining the well-known disturbances in calcium homeostasis in AD (Ito et al., 1994; Leissring et al., 1999a Leissring et al., , 1999b Nelson et al., 2007; Small, 2009; Smith et al., 2005; Yu et al., 2009) . These calcium perturbations would likely affect many downstream processes, such as intra-and inter-neuronal signaling, regulation of biochemical pathways, apoptosis, and mitochondrial dynamics. Finally, increased intracellular calcium due to MAM dysfunction may activate calcium-regulated kinases that phosphorylate tau, as proposed initially by Hardy and Higgins (1992) . While no mutations in tau have been found to cause FAD, we note that a mutation in tau (P301L) associated with familial frontotemporal dementia (FTD) caused an increased association between ER and mitochondria in a transgenic mouse model of the disease (Perreault et al., 2009) . It might be useful to determine whether patients with FTD have features of MAM dysfunction, altered Aβ processing, and increased neuritic plaques, a possibility supported by the finding of amyloidpositive plaques in the brains of a number of FTD patients with both the P301L and R406W mutations (Rosso et al., 2000; van Swieten et al., 1999) .
MAM, lipid rafts, and APP processing
How does the MAM hypothesis explain the production of Aβ (and more specifically, the increased ratio of Aβ 42 :Aβ 40 )? We believe that the answer to this question lies in the biophysical properties of lipid rafts and the role that MAM plays in maintaining the alignment of γ-secretase to its substrate, APP.
As a lipid raft-like domain, MAM has a higher concentration of cholesterol than does the surrounding ER membrane (Lingwood and Simons, 2010) and it is physically thicker (Risselada and Marrink, 2008; Simons and Vaz, 2004) ; MAM probably also has a different degree of curvature (Chaudhuri and Chattopadhyay, 2011 ) and a different composition of phospholipid fatty acid species and degree of unsaturation (Chaudhuri and Chattopadhyay, 2011; Kucerka et al., 2009 ). Higher concentrations of cholesterol are known to make membranes more rigid and transform them into liquid-ordered domains. However, the thickness of a membrane depends more strongly on the acyl chain length and degree of unsaturation of its phospholipids than it does on its cholesterol level (Janmey and Kinnunen, 2006) . Compared to phospholipids in non-raft membranes, those in raftlike domains tend to contain longer and more saturated acyl chains that increase relative membrane thickness and facilitate target proteins to partition into these liquid-ordered domains (Simons and Vaz, 2004) . Therefore, changes in the phospholipid composition of these raft-like domains (and hence, in MAM) will affect the behavior of the proteins embedded within them. Furthermore, the specific lipid composition of raft-like membranes favors "hydrophobic matching" between the thickness of a protein's transmembrane (TM) domain (e.g. the C-terminal region of APP) and the bilayer thickness in which it resides (Kaiser et al., 2011) , and promotes a redistribution of TM peptides and lipids according to hydrophobic length.
With respect to AD, Winkler et al. (2012) have recently shown that by changing the lipid environment of γ-secretase residing in model membranes in vitro, APP cleavage can be quantitatively and qualitatively altered. Specifically, thicker membranes favor the production of Aβ 40 , whereas thinner ones favor Aβ 42/43 (Winkler et al., 2012) , but the mechanism by which this occurs is unclear. Thus, in AD, it is possible that the thickness of the ER membrane at the MAM changes, owing to the presumed alterations in its lipid and protein composition. In this case, the APP C-terminal TM domain spanning the MAM is now mismatched with respect to the new bilayer thickness, resulting in a reorientation of the APP TM domain within the bilayer to adapt to the mismatch (Sobhanifar et al., 2010) . We note that presenilin, a rhomboid-like aspartyl protease that cleaves its substrate within membranes, has no sequence specificity; in essence it "cuts what it sees," but apparently in an ordered fashion (a "product line" (Chavez-Gutierrez et al., 2012; Golde et al., 2012; Qi-Takahara et al., 2005) ) of longerto-shorter peptides. We speculate that in normal cells, the cleavage of APP results in a distribution of Aβ peptides with an average length centered on 40 aa, but with lengths ranging from~37 to~48 aa (Czirr et al., 2008) . In AD, however, there is a shift in this distribution to longer sizes, with the average Aβ length centered on 42 aa, perhaps due to changes in the tilt and elongation of the PS1 C-terminal transmembrane domain (Sobhanifar et al., 2010; Winkler et al., 2012) . We propose that the causes of this shift will turn out to be factors that alter MAM lipid composition (Schon and Area-Gomez, 2010) .
Another way to explain the shift in Aβ species, at least in FAD, has been proposed by Berezovska's group, who showed that changes in the alignment of PS1 with the C-terminal intramembranous domain of APP (i.e. the region that is cleaved by γ-secretase) alters the positioning of the PS1/γ-secretase cleavage site on APP such that more Aβ 42 and less Aβ 40 is produced (Herl et al., 2009; Uemura et al., 2009; Uemura et al., 2011) . In other words, normal PS1 cleaves normal APP to produce mainly Aβ 40 , whereas mutant APP affects the position of the γ-cleavage site of normal PS1, and conversely, mutant PS1 affects the position where it cleaves normal APP, in both cases producing more Aβ 42 (Berezovska et al., 2005; Uemura et al., 2011) . This model is consistent with recent data showing that PS1 mutations alter the active site conformation of γ-secretase (Chau et al., 2012) , and would also be consistent with an altered lipid milieu as playing a role in determining the physical apposition of PS1 to APP (Sobhanifar et al., 2010) .
Concluding remarks
While the presence of presenilins and γ-secretase activity in MAM is consistent with the amyloid cascade hypothesis, we feel that the plaques and tangles found in AD are not the fundamental cause of the disease (although they certainly exacerbate its course and progression). Rather, we propose that the underlying cause of AD is a pathological increase in MAM functionality and in the communication between ER and mitochondria. From this perspective, any factor that increases MAM behavior and/or ER-mitochondrial connectivity could conceivably cause AD (Fig. 4) ; γ-secretase is merely one such factor. Furthermore, these MAM-mediated disturbances could help explain many of the disparate features of the disease, including not only the formation of plaques and tangles, but also many of the "other" features of the disease discussed above (Fig. 5) . We note that the alterations in MAM found by us in non-neuronal tissuenamely fibroblasts -from AD patients (Area-Gomez et al., 2012) is consistent with the finding of alterations in non-neuronal tissues in AD patients, such as liver (Astarita et al., 2010) , dermal tissue (Joachim et al., 1989) , intestine (Joachim et al., 1989) , fibroblasts (Gibson and Huang, 2002; Pani et al., 2009a Pani et al., , 2009b Peterson and Goldman, 1986) , vascular cells (Zlokovic, 2011) , and blood erythrocytes (Markesbery et al., 1980) , mononuclear cells (Pani et al., 2009a (Pani et al., , 2009b , and platelets (Zubenko et al., 1987) . Thus, it may well be that AD is essentially a body-wide disorder with a brain-specific clinical phenotype (Joachim et al., 1989) .
We believe that the "MAM hypothesis" offers a potentially unified and coherent explanation for many of the features of Alzheimer disease (Fig. 5) . Besides providing a different way of thinking about AD pathogenesis, it also has the potential of redirecting efforts aimed at diagnosis and treatment. For example, it might be more useful to design a treatment strategy aimed at "fixing" the MAM rather than trying to deal with the accumulation of plaques and tangles, which we consider to be downstream consequences of increased MAM function and increased ER-mitochondrial connectivity. In addition, it might be possible to exploit this upregulation by using it as a marker to diagnose AD. While the MAM hypothesis will almost certainly require modification in its particulars, we believe that the finding of increased communication between ER and mitochondria in AD cells, and the observation that many of the biochemical and morphological features of AD are consistent with what is currently known about MAM biochemistry and biology, is sufficiently compelling to warrant further investigation.
